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In most healthy mammalian cells an uneven distribution of the mixture of the phospholipid 
species that make up the bilayer cell membrane is maintained between inner and outer layers: 
anionic species (principally phosphatidylserine, PS) are arranged largely on the inner layer.
1
 
In some abnormal cells this is not the case and a considerable amount of anionic lipids are 
displayed on the outer membrane surface; this is known in cells undergoing the 
early/intermediate stages of apoptosis (programmed cell death),
2
 tumour vasculature,
3
 
bacteria and viruses.
4
 
 Detection and imaging of apoptotic cells in vivo is desirable, as a clinical and research tool: 
the extent and speed of onset of apoptosis in tumours following a treatment has shown to be a 
good prognostic indicator of treatment outcome.
5
 In vitro, apoptotic cells are typically 
detected using biomolecules known to bind phosphatidylserine, conjugated with fluorescent 
moieties; the most extensively used in this context has been Annexin V.
6
 For in vivo imaging, 
Annexin V and others have been modified with various functionalities for imaging, for 
example with radioactive,
7
 optical,
8
 and, particularly of interest here, MRI probes.
9-12
 While 
this approach has proved somewhat successful, bioconjugates are bulky (36 kDa in the case 
of Annexin V), limiting the density with which the ‘payload’ may be delivered and, 
ultimately, sensitivity. Small molecule probes are desirable for their ease of synthesis, 
robustness, long shelf life, fast binding kinetics, fast clearance from blood circulation, and 
ease of formulation for widespread use.
13
  
In recent years, the potential of Zn
2+
-2,2’-dipicolylamine (ZnDPA) to recognise phosphate 
moieties, and especially phosphorylated biomolecules, has been increasingly realised. Smith 
has developed a range of bis-ZnDPA complexes as probes able to recognise apoptotic and 
bacterial cells, which they have demonstrated with considerable success both in vitro 
(liposomal models and cells)
14,15
 and in small animal tumour and bacterial infection models, 
using NIR optical imaging.
16,17
  
 In a recently-published study we showed that bis-ZnDPA, lanthanide complexes 
[Ln(L)Zn2](NO3)4 (Ln = Gd, Eu; see Scheme 1), bind strongly to polyanionic species, 
including Fmoc-phosphoserine.
18
 This prompted us to study whether this complex might also 
bind bisanionic phosphoserine head groups at membrane surfaces. Here we present a study of 
the interaction between [Eu(L)Zn2](NO3)4 and phosphatidylserine derivatives on the surface 
of cell membrane models (unilamellar vesicles) and preliminary studies of [Gd(L)Zn2](NO3)4  
as an MRI contrast agent targeted to anionic membrane species in cell cultures. 
 Scheme 1  Structures of phospholipids, sensitiser, and [Ln(L)Zn2]
4+
. 
 
 Unilamellar vesicles are established models for apoptotic cell membranes for in vitro 
assessment of potential probes, and are produced using standard extrusion procedures from 
mixtures of commercially-available phospholipids. We have followed protocols adapted from 
those established by DiVittorio et al
15
  to study the interaction of [Eu(L)Zn2](NO3)4 with 
DOPS (a synthetic phosphatidylserine derivative with the same polar head group – see 
Scheme 1), with the addition of 2,3-Napthalimide (2,3-Nap, 8.3 mol%) to the lipid mixtures 
prior to extrusion.
†
 2,3-Nap is known to sensitise Eu
3+
 emission when incorporated 
covalently into Eu-bearing dendrimers,
19
 or by hydrophobic interactions into Eu-bearing 
micelles.
20
 We propose that intermolecular energy transfer may be used to detect the 
proximity of [Eu(L)Zn2](NO3)4 to a membrane incorporating 2,3-Nap (by hydrophobic 
interactions), on reversible recognition of surface species, as schematically shown in Fig 1. 
 
 Figure 1 Schematic representation of sensitisation of Eu
3+
-centred emission by 
naphthalimide on recognition of membrane species. 
 
 
    A series of vesicles were produced to demonstrate this, and the emission spectra (λex = 335 
nm) resulting from their interaction (or lack of it) with [Eu(L)Zn2](NO3)4 are summarised in 
Fig 2: solutions contained [Eu(L)Zn2](NO3)4 along with vesicles formed from lipid mixtures 
with either 1:1 DOPS:DOPC (1),  1:1 DOPS:DOPC with 2,3-Nap (1-S) or DOPC with 2,3-
Nap (2-S)  (see Scheme 1 for chemical structures). Strong characteristic Eu-centred emission 
bands were only observed in solution 1-S, where vesicles contained both 2,3-Nap and DOPS; 
in the others; where vesicles lacked this combination, and in solutions of the complex alone, 
little emission was observed. This suggests that only on selective recognition of the anionic 
DOPS headgroup by [Eu(L)Zn2](NO3)4 is the Eu
3+
 centre brought sufficiently close to the 
bilayer-incorporated 2,3-Nap for energy transfer to occur (as in Fig 1). This mechanism is 
further corroborated by the dramatic decrease of Eu-centred emission on addition of 
pyrophosphate (previously shown is very strongly bound by [Eu(L)Zn2]
4+
),
18
 demonstrating 
the reversible nature of the recognition by an intact complex, as opposed to dissociation of 
the Eu
3+
 cation induced by the anionic DOPS head group (see Fig. S2 in the ESI). To confirm 
this further we added the zinc-free [Eu(L)] complex to 1-S and recorded the emission. As can 
be seen in Fig. S3, the emission in this case was much lower than when [Eu(L)Zn2](NO3)4 
was used (the emission recorded likely be due to a small degree of non-specific binding by 
[Eu(L)]).  
 
 
Figure 2  Results from interaction of [Eu(L)Zn2]
4+
 with a variety of vesicles (λex = 335 
nm; excitation and emission slit width are 5 nm and 1 nm respectively). 
Notable sensitisation only takes place in DOPS/naphthalimide -bearing 
vesicles (1-S), where recognition by [Eu(L)Zn2]
4+
 may occur (spectrum of 
highest intensity, coloured red). 
 
With the reasonable presumption of an even distribution of DOPS between inner and outer 
leaflets of the membrane bilayer in vesicles of this size,
21
 it was possible to construct a Job’s 
plot consistent with 1:1 binding (Fig. 3, inset). DOPS-containing vesicles (1-S) were then 
titrated with [Eu(L)Zn2](NO3)4,
†
 with the resulting variation in emission at 614 nm shown in 
Fig 3; an association constant (Ka) of 1.81x10
4 
M
-1
 for recognition of the available (outer 
surface) DOPS by [Eu(L)Zn2](NO3)4 was estimated (fitting data to a standard 1:1 model –
Fig. 3 and ESI). 
 
 
Figure 3  Emission data (614 nm) from titration; line indicates non-linear curve fitting. 
The inset shows Job plot indicating a 1:1 interaction between complex and 
DOPS exposed on the surface of vesicles (1-S). 
 
 
Given these encouraging results showing recognition of the PS head group on the surface of 
cell models, we proceeded to a preliminary MRI study, using [Gd(L)Zn2](NO3)4 as a contrast 
agent for imaging of cells in which apoptosis had been induced. In a protocol similar to that 
previously reported to assess apoptosis-targeting contrast media,
9,22
 a murine lymphoma 
(EL4) cell culture was grown, split in two, and apoptosis induced in one population by 
incubation in etoposide (15 µM). Proportions of early-stage apoptosis, necrosis, and viable 
cells in both populations were determined by flow cytommetry (double-staining with 
propidium iodide and annexin V-FITC; Fig. S4 in ESI). In the untreated cells, 84% remained 
viable, with 11% necrotic and negligible amounts found to be early apoptotic; by contrast, 
only 38% of etopside-treated cells remained viable, with 19% necrotic and 19% found to be 
early apoptotic. Samples of each population were incubated with varying contrast agent 
concentrations (0, 100, 300 and 600 µM) at room temperature for 30 min; they were collected 
by centrifugation, the unbound contrast agent removed by washing with saline and the cell 
pellet re-suspended in saline (with 1% agarose to stop cell sedimentation) and loaded into 250 
µl PCR tubes for MRI imaging. Relaxation rates (1/T1) and image intensity (T1-weighted 
image) are shown in Figs. 4 and 5, respectively, with selected T1-weighted images inset of 
Fig. 5. Considerable differences in T1 between the etoposide-treated and untreated 
populations were observed, even when incubated with low concentrations of 
[Gd(L)Zn2](NO3)4. As a consequence, large differences between the two populations were 
clearly observable in T1-weighted images (both by inspection and quantification of intensity) 
in the presence of 300 µM or greater [Gd(L)Zn2](NO3)4, with negligible enhancement of 
intensity in the untreated populations, even after incubation with 600 µM [Gd(L)Zn2](NO3)4. 
 
 
Figure 4 MR relaxation rate (1/T1) of Etoposide-treated and untreated cells with varying 
concentrations of the contrast agent: the Etoposide-treated cells manifest 
increased binding of [Gd(L)Zn2]
4+
 in a greater increase in relaxation rate 
(1/T1) than untreated cells as the concentration of contrast agent is increased. 
(* = p < 0.05). 
 
 
 
 
  
 
 
Figure 5 MR signal intensity in T1-weighted (TR = 0.7 s) image of Etoposide-treated 
and untreated cells with varying concentrations of the contrast agent: 
Etoposide-treated cells show a considerable increase in signal intensity as the 
concentration of contrast agent is increased, while that of untreated  cells is 
very small by comparison. (* = p < 0.05).  
 
 
Taken together these results make it clear that the treated cells interact with 
[Gd(L)Zn2](NO3)4 considerably more strongly, despite only relatively small differences in 
cell viability (only ca. 1/5 being identified as early apoptotic in treated population). While 
there is some measurable 1/T1 increase in the untreated population on interaction of 
[Gd(L)Zn2](NO3)4, non-specific binding is unsurprising in mixed cell populations (>10% 
necrotic) and the enhancement may stem from a  number of mechanisms:
‡
 it is not sufficient 
to prevent clear differentiation between increasing concentrations on inspection of their 
images. This selectivity is consistent with the high selectivity for apoptotic cells previously 
reported in a wide and structurally diverse range of bis-(Zn-DPA) complexes.
14,15,17
 As such 
we feel that these positive results should encourage the development of small Gd
3+
-bis(Zn-
DPA) complexes as MRI probes for apoptosis, as an alternative to the continued development 
of bioconjugate-based probes. Although neutral Gd-DTPA-bis(amide) complexes have been 
used clinically for some time, their in vivo stability has been recently questioned,
23
 especially 
when interacting with cell surfaces.
24
 Were this to prove problematic, macrocyclic Gd
3+
 
complexes with two pendant Zn-DPA moieties are likely to prove more robust in vivo.  
 In conclusion, we have demonstrated in vitro and in cellulo the ability of [Ln(L)Zn2](NO3)4 
to target clinically important anionic membrane species, both in synthetic cell models and in 
cell cultures, and shown it possible to use [Gd(L)Zn2](NO3)4 as a contrast agent for the 
differentiation of apoptotic cultures in MRI images. Furthermore, we have demonstrated a 
novel method for studying the interaction of Ln
3+
 complexes with membrane species, which 
may be more broadly applicable either as demonstrated, using different membrane-bound 
targets, or in an inverse configuration with energy transfer to amphiphilic lanthanide(III) 
species  bound in a membrane.
20
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Notes and references 
† Electronic Supplementary Information (ESI) available: preparation of [Ln(L)Zn2](NO3)4, 
preparaton of liposomes, luminescence experiments, preparation of cell cultures, and MRI 
imaging of cell samples. See DOI: XXX 
 
‡ Interaction with the untreated cell population may be due to non-specific binding of viable 
cells (not unlikely for a positively-charged complex in saline, an extremely uncompetitive 
medium, but less likely in vivo), incomplete removal of unbound complex, binding of the tiny 
population of apoptotic cells present, induction of apoptosis, dissociation of Gd
3+
 from the 
ligand, or binding of necrotic cells. Differentiation between these possibilities is beyond the 
scope of this preliminary study. 
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